Does the media prefer AQST or RAPP?

In the previous week, Aquestive Therapeutics had 6 more articles in the media than Rapport Therapeutics. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 11 mentions for Rapport Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.88 beat Rapport Therapeutics' score of 0.87 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AQST or URGN more profitable?

Urogen Pharma has a net margin of -51.73% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -144.63% N/A -52.40% Urogen Pharma -51.73% N/A -43.79%

Does the media favor AQST or URGN?

In the previous week, Aquestive Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 12 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.35 beat Aquestive Therapeutics' score of 0.88 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLYS or AQST?

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 15 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.11 beat Aquestive Therapeutics' score of 0.88 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HRMY or AQST?

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 16 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.59 beat Aquestive Therapeutics' score of 0.88 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aquestive Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HCM or AQST?

HUTCHMED has higher revenue and earnings than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.94 $456.91M N/A N/A Aquestive Therapeutics $54.09M 11.65 -$83.78M -$0.65 N/A

Is HCM or AQST more profitable?

HUTCHMED has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Aquestive Therapeutics -144.63% N/A -52.40%

Does the media favor HCM or AQST?

In the previous week, Aquestive Therapeutics had 11 more articles in the media than HUTCHMED. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 6 mentions for HUTCHMED. Aquestive Therapeutics' average media sentiment score of 0.88 beat HUTCHMED's score of 0.71 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aquestive Therapeutics (AQST) Competitors

$5.02 -0.14 (-2.71%)

As of 08/28/2026 04:00 PM Eastern

Compare

AQST vs. RAPP, URGN, MLYS, HRMY, and HCM

Should you buy Aquestive Therapeutics stock or one of its competitors? Aquestive Therapeutics's main competitors and comparable companies include Rapport Therapeutics (RAPP), Urogen Pharma (URGN), Mineralys Therapeutics (MLYS), Harmony Biosciences (HRMY), and HUTCHMED (HCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aquestive Therapeutics compare to Rapport Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Aquestive Therapeutics had 6 more articles in the media than Rapport Therapeutics. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 11 mentions for Rapport Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.88 beat Rapport Therapeutics' score of 0.87 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aquestive Therapeutics has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$54.09M	11.65	-$83.78M	-$0.65	N/A
Rapport Therapeutics	$20M	116.99	-$111.48M	-$3.04	N/A

Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Aquestive Therapeutics presently has a consensus price target of $8.80, suggesting a potential upside of 75.30%. Rapport Therapeutics has a consensus price target of $62.86, suggesting a potential upside of 28.88%. Given Aquestive Therapeutics' higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

32.5% of Aquestive Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aquestive Therapeutics beats Rapport Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Urogen Pharma?

Aquestive Therapeutics (NASDAQ:AQST) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Urogen Pharma has a net margin of -51.73% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Urogen Pharma	-51.73%	N/A	-43.79%

Aquestive Therapeutics currently has a consensus target price of $8.80, indicating a potential upside of 75.30%. Urogen Pharma has a consensus target price of $50.38, indicating a potential upside of 15.49%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Aquestive Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$54.09M	11.65	-$83.78M	-$0.65	N/A
Urogen Pharma	$109.79M	19.42	-$153.49M	-$1.98	N/A

In the previous week, Aquestive Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 12 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.35 beat Aquestive Therapeutics' score of 0.88 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aquestive Therapeutics and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Mineralys Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 15 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.11 beat Aquestive Therapeutics' score of 0.88 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics presently has a consensus price target of $49.33, indicating a potential upside of 92.71%. Aquestive Therapeutics has a consensus price target of $8.80, indicating a potential upside of 75.30%. Given Mineralys Therapeutics' higher possible upside, equities research analysts clearly believe Mineralys Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mineralys Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aquestive Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Aquestive Therapeutics	$54.09M	11.65	-$83.78M	-$0.65	N/A

Summary

Aquestive Therapeutics beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Harmony Biosciences has a net margin of 18.88% compared to Aquestive Therapeutics' net margin of -144.63%. Harmony Biosciences' return on equity of 20.06% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Harmony Biosciences currently has a consensus price target of $47.11, indicating a potential upside of 20.15%. Aquestive Therapeutics has a consensus price target of $8.80, indicating a potential upside of 75.30%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Harmony Biosciences has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$959.90M	2.38	$158.69M	$3.08	12.73
Aquestive Therapeutics	$54.09M	11.65	-$83.78M	-$0.65	N/A

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 16 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.59 beat Aquestive Therapeutics' score of 0.88 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Aquestive Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harmony Biosciences beats Aquestive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

HUTCHMED has higher revenue and earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.94	$456.91M	N/A	N/A
Aquestive Therapeutics	$54.09M	11.65	-$83.78M	-$0.65	N/A

HUTCHMED has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 11 more articles in the media than HUTCHMED. MarketBeat recorded 17 mentions for Aquestive Therapeutics and 6 mentions for HUTCHMED. Aquestive Therapeutics' average media sentiment score of 0.88 beat HUTCHMED's score of 0.71 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED presently has a consensus target price of $14.87, indicating a potential upside of 20.09%. Aquestive Therapeutics has a consensus target price of $8.80, indicating a potential upside of 75.30%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

HUTCHMED has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Summary

Aquestive Therapeutics beats HUTCHMED on 10 of the 14 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$630.07M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-7.72	787.65	273.16	25.45
Price / Sales	11.65	792.89	605.01	76.63
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	-11.16	11.97	12.98	6.14
Net Income	-$83.78M	$2.83B	$3.48B	$348.86M
7 Day Performance	7.73%	0.39%	0.13%	-0.80%
1 Month Performance	34.95%	5.34%	7.08%	4.13%
1 Year Performance	33.16%	6.05%	24.67%	15.17%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	2.4192 of 5 stars	$5.02 -2.7%	$8.80 +75.3%	+33.2%	$630.07M	$54.09M	N/A	160	Analyst Revision
RAPP Rapport Therapeutics	2.9986 of 5 stars	$48.25 +0.8%	$62.86 +30.3%	+176.6%	$2.31B	$20M	N/A	N/A	Insider Trade
URGN Urogen Pharma	2.8848 of 5 stars	$46.83 +0.1%	$50.38 +7.6%	+124.3%	$2.29B	$109.79M	N/A	200	Positive News
MLYS Mineralys Therapeutics	2.8521 of 5 stars	$25.89 +0.5%	$49.33 +90.5%	+65.4%	$2.29B	N/A	N/A	28	Insider Trade
HRMY Harmony Biosciences	4.5547 of 5 stars	$38.09 +0.1%	$45.50 +19.5%	+6.3%	$2.22B	$959.90M	12.37	200	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. RAPP, URGN, MLYS, HRMY, and HCM

How does Aquestive Therapeutics compare to Rapport Therapeutics?

Summary

How does Aquestive Therapeutics compare to Urogen Pharma?

Summary

How does Aquestive Therapeutics compare to Mineralys Therapeutics?

Summary

How does Aquestive Therapeutics compare to Harmony Biosciences?

Summary

How does Aquestive Therapeutics compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. RAPP, URGN, MLYS, HRMY, and HCM

How does Aquestive Therapeutics compare to Rapport Therapeutics?

Does the media prefer AQST or RAPP?

Which has better valuation and earnings, AQST or RAPP?

Which has more volatility and risk, AQST or RAPP?

Is AQST or RAPP more profitable?

Do analysts prefer AQST or RAPP?

Do institutionals & insiders hold more shares of AQST or RAPP?

Summary

How does Aquestive Therapeutics compare to Urogen Pharma?

Is AQST or URGN more profitable?

Do analysts prefer AQST or URGN?

Do institutionals and insiders have more ownership in AQST or URGN?

Which has more volatility & risk, AQST or URGN?

Which has preferable valuation and earnings, AQST or URGN?

Does the media favor AQST or URGN?

Summary

How does Aquestive Therapeutics compare to Mineralys Therapeutics?

Which has more volatility and risk, MLYS or AQST?

Does the media favor MLYS or AQST?

Do analysts prefer MLYS or AQST?

Is MLYS or AQST more profitable?

Do institutionals & insiders have more ownership in MLYS or AQST?

Which has stronger earnings & valuation, MLYS or AQST?

Summary

How does Aquestive Therapeutics compare to Harmony Biosciences?

Which has more risk & volatility, HRMY or AQST?

Is HRMY or AQST more profitable?

Do analysts prefer HRMY or AQST?

Which has better valuation & earnings, HRMY or AQST?

Do institutionals and insiders have more ownership in HRMY or AQST?

Does the media favor HRMY or AQST?

Summary

How does Aquestive Therapeutics compare to HUTCHMED?

Which has higher earnings and valuation, HCM or AQST?

Which has more volatility & risk, HCM or AQST?

Do insiders and institutionals have more ownership in HCM or AQST?

Does the media favor HCM or AQST?

Do analysts rate HCM or AQST?

Is HCM or AQST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools